Navigation Links
New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Date:10/3/2007

Lowest Dose of Estradiol Shown to Be Safe and Effective for Menopausal

Women

WEST PALM BEACH, Fla., Oct. 3 /PRNewswire/ -- A study presented today at the 2007 Annual Meeting of the North American Menopause Society (NAMS) revealed that Divigel(R) (estradiol gel) 0.1% significantly reduced the frequency and severity of moderate to severe hot flashes associated with menopause. Additional data presented at the meeting found that Divigel(R) is a safe and well-tolerated therapy offering the lowest approved dose of estradiol available for the treatment of hot flashes, the most common symptom of menopause.

"These data demonstrate that Divigel(R) is a safe and highly effective low dose therapy that quickly manages the uncomfortable side effects of menopause," said Dr. Ronald Ackerman, FACOG, CEO and principal investigator, Comprehensive Clinical Trials. "Women that have been reluctant to take older hormone therapies with higher doses of estrogen now have the choice of taking Divigel(R), the lowest dose of estradiol available."

Guidelines from the North American Menopause Society (NAMS) indicate that estrogen hormone therapy should be used at the lowest effective dose for the shortest amount of time.

"Divigel(R) is applied to the skin where it absorbs directly into the bloodstream without having to pass through the liver. This provides treatment continuity allowing women to use less estrogen than is needed in a pill because of the way the therapy is delivered," said Dr. Ackerman. "Transdermal therapies have been used in Europe for years, and they are becoming increasingly common in the United States. The availability of this lowest dose estrogen gel combined with its convenience makes Divigel(R) a valuable option for physicians and patients."

This 12-week study evaluated 488 postmenopausal women presenting with moderate to severe vasomotor symptoms. The study compared placebo to Divigel(R) at doses of 1.0 g gel/day, 0.5 g gel/day and 0.25 g gel/day. Approximately 120 patients were randomized to each treatment group. Study endpoints included mean change from baseline in daily frequency and severity of moderate to severe hot flashes.

Consistent with FDA requirements, both the Divigel(R) 0.5 g and 1.0 g treatment groups demonstrated a statistically significant reduction in the frequency and severity of vasomotor symptoms by week four. The Divigel(R) 0.25 g group demonstrated a statistically significant reduction in the frequency and severity of vasomotor symptoms by week seven. Statistically significant differences were maintained through the duration of treatment (12 weeks). Divigel(R) also had an excellent tolerability profile and less than one percent of patients experienced skin irritation reactions at the treatment application site.

Divigel(R) was approved by the U.S. Food and Drug Administration (FDA) in June 2007. The estrogen in Divigel(R) is derived from plant sources and is identical to the primary estrogen produced by a woman's ovaries before menopause. Divigel(R) is a quick-drying gel that is odorless when dry, and is available in convenient, individual-use packets. One packet of gel is applied daily to an area that measures approximately 5 x 7 inches on the thigh, the smallest application area compared to all other available gel or lotion estrogen products. Divigel(R) also offers dosing flexibility with three different strengths (0.25 mg estradiol/day, 0.5 mg estradiol/day and 1.0 mg estradiol/day) to individualize treatment for each woman.

For more information, call 1-800-654-2299 or visit http://www.divigelus.com.


'/>"/>
SOURCE Comprehensive Clinical Trials
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
2. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
3. Waismann Method Survey Reveals Dependency Risk for People Using Suboxone
4. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
5. Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers
6. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
7. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
8. First-of-its-Kind National Report Reveals Estimated High Prevalence and Heavy Cost of Type 2 Diabetes Complications in America
9. Over 10,000 UK Breast Cancer Patients Could Become Eligible Within the Next Year for a Breast Cancer Therapy Showing Increased Survival Rates, Reveals Synovate Healthcare’s European Oncology Monitor
10. Survey Reveals Significant Public Lack of Diabetes Awareness
11. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):